# Jenburkt Pharmaceuticals share price (Jenburkt Pharmaceuticals Ltd, BSE: 524731) > Jenburkt Pharmaceuticals share price: ₹1,128.10 at the BSE close on 24 June 2026, the latest close in our records; down 13.7% in the year to that date. Jenburkt Pharmaceuticals (BSE: 524731) is worth ₹498 crore, trades at a P/E of 14.3 and has closed between ₹1,000.30 and ₹1,377.75 over the past 52 weeks. > Jenburkt Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +8.4% in a year while the price moved −13.7%. 524731 · Pharma - Others · data as of 24 June 2026. Page: https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Growing steadily, from fewer quarters than usual - Price: ₹1,128.10 (−13.7% in a year) - P/E: 14.3× (higher than 59% of the last 10 years) - Revenue (Mar 2026): ₹45.0 Cr (+9.8% on a year ago) - Profit (Mar 2026): ₹11.0 Cr (+22.2% on a year ago) - Operating margin: 31.1% (+4.3 points on a year ago) - ROCE: 27%, FY26 - ROIC: 21.5%, against a 12.0% cost of capital: +9.5 points Biggest thing to watch: the price has already been rising for 3 weeks, so timing is the risk more than the business. ## What is the Jenburkt Pharmaceuticals share price? Jenburkt Pharmaceuticals Ltd's share price was ₹1,128.10 at the close on 24 June 2026. It has been rising for 3 weeks. That is 2.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,000 and ₹1,378, and at that close it sat 34% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row. Over the last 10 years the share price moved +145% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Jenburkt Pharmaceuticals this quarter? Three changes stood out: best operating margin in 13 quarters, revenue up on a year earlier for 9 quarters in a row (every quarter we can compare) and promoters cut their stake for 6 quarters in a row. 1. Best operating margin in 13 quarters Operating margin was 32% in the March 2026 quarter, against 26% a year earlier. 2. Revenue up on a year earlier for 9 quarters in a row (every quarter we can compare) In the March 2026 quarter revenue was ₹45 crore, +9.8% on a year earlier. 3. Promoters cut their stake for 6 quarters in a row From 46.7% to 46.6% of the company by the March 2026 quarter. ## What are Jenburkt Pharmaceuticals' latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Jenburkt Pharmaceuticals reported revenue of ₹45.0 crore, up 9.8% from ₹41.0 crore a year earlier, and a profit of ₹11.0 crore, up 22.2% from ₹9.00 crore. ### Jenburkt Pharmaceuticals results: January to March 2026 against a year earlier | Measure | January to March 2026 | January to March 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹45.0 crore | ₹41.0 crore | +9.8% | | Profit | ₹11.0 crore | ₹9.00 crore | +22.2% | | Earnings per share | ₹24.58 | ₹19.35 | +27.0% | | Operating margin | 31.1% | 26.8% | +4.3 points | The next results, for April to June 2026, are due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.) ## What is the Jenburkt Pharmaceuticals share price history? Jenburkt Pharmaceuticals closed at ₹1,128.10 on 24 June 2026, down 13.7% from ₹1,307.35 a year earlier (27 June 2025) and up 131.2% over five years. Its highest weekly close since May 2016 was ₹1,377.75 on 4 July 2025. ### Jenburkt Pharmaceuticals share price: then and now | When | Close | Change to 24 Jun 2026 | | --- | --- | --- | | 1 week ago · 17 Jun 2026 | ₹1,148.90 | −1.8% | | 1 month ago · 22 May 2026 | ₹1,154.70 | −2.3% | | 6 months ago · 26 Dec 2025 | ₹1,074.70 | +5.0% | | 1 year ago · 27 Jun 2025 | ₹1,307.35 | −13.7% | | 3 years ago · 23 Jun 2023 | ₹717.35 | +57.3% | | 5 years ago · 25 Jun 2021 | ₹488.00 | +131.2% | | 10 years ago · 24 Jun 2016 | ₹383.90 | +193.9% | | Earliest weekly close in our records · 13 May 2016 | ₹460.50 | +145.0% | | Highest weekly close since May 2016, also the 52-week high · 4 Jul 2025 | ₹1,377.75 | −18.1% | | Lowest weekly close since May 2016 · 3 Apr 2020 | ₹298.10 | +278.4% | | 52-week low (weekly close) · 6 Mar 2026 | ₹1,000.30 | +12.8% | Weekly closing prices. Each change is the move from that price to the 24 Jun 2026 close. A day's intraday high or low can go beyond these weekly closes. (532 weekly closes from 13 May 2016 to 24 June 2026.) ## What is the latest news on Jenburkt Pharmaceuticals? 24 Jun 2026: Jenburkt Pharmaceuticals closed at ₹1,128.10, down 1.8% on the week and down 2.3% on the month. Results for January to March 2026: Revenue up 9.8% and profit up 22.2% on a year earlier. ## What dividend does Jenburkt Pharmaceuticals pay? Yes. Jenburkt Pharmaceuticals Ltd paid out 26% of its profit as dividends in FY26, and it paid a dividend in each of its last 12 reported years. This page shows the payout as a share of profit, not an amount per share (as of 24 June 2026). ## What to watch in Jenburkt Pharmaceuticals' next results? When Jenburkt Pharmaceuticals reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Mar 2026 quarter, revenue was +9.8% on a year earlier, and the last four quarters averaged +11.8%. - Whether the operating margin stays near 31.1%. It is 4.3 percentage points higher than four quarters earlier. - Net profit against the same quarter a year earlier. In the Mar 2026 quarter, profit was +22.2% on a year earlier. - Whether cash from operations catches up with profit. Only 68% of the last 3 years' profit came in as cash from operations. ## Which stock lists is Jenburkt Pharmaceuticals on? Jenburkt Pharmaceuticals is not on any of our India lists this week. ## Is Jenburkt Pharmaceuticals profitable? Jenburkt Pharmaceuticals Ltd earned ₹11.0 Cr of net profit in the Mar 2026 quarter, +22.2% on the same quarter a year earlier. Full-year FY26 profit was ₹35.0 Cr. Over 10 years profit has grown 12.3% a year on average. The Mar 2026 quarter's profit is 24.4% of that quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr. For the full year, FY26 profit was ₹35.0 Cr (+9.4% on the year before). Why profit moved: revenue changed +9.8% on a year earlier and the margin moved +4.3 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +5.5% and revenue +11.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Jenburkt Pharmaceuticals make, and is it growing? Jenburkt Pharmaceuticals Ltd reported ₹45.0 Cr of revenue in the Mar 2026 quarter, +9.8% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 6.0% a year on average. The last full year, FY26, came in at ₹169 Cr. The last four reported quarters add to ₹170 Cr. FY26 revenue was ₹169 Cr, +11.2% on the year before. Recent pace: the last four quarters grew +11.8% on average, against 6.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.8%, against +9.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +6.1%, against +18.3% a year (rolling over). ## How much of every ₹100 of sales does Jenburkt Pharmaceuticals keep? Jenburkt Pharmaceuticals Ltd's operating margin was 31.1% in the Mar 2026 quarter, 4.3 percentage points higher than the same quarter a year ago. Across 12 years it has been between 16.8% and 26.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +5.5 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Jenburkt Pharmaceuticals' profit turning into cash? Over the last 3 years, 68% of Jenburkt Pharmaceuticals Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹27.0 Cr of operating cash against ₹35.0 Cr of profit. After ₹13.0 Cr of estimated spending on assets (worked out from the change in fixed assets plus depreciation; no filed figure), ₹14.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 68% of profit came in as cash: the cash cycle got 32 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 32 days longer. The next section looks at where the cash is stuck. ## Where does Jenburkt Pharmaceuticals' cash go? Jenburkt Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 115 days in FY26, up from 83 days in FY21. It spent ₹62.0 Cr on assets over the last 3 years. Customers take 53 days to pay, and stock sits for 154 days on average. At FY26 sales of ₹169 Cr, each day of that cycle ties up about ₹0.5 Cr, so roughly ₹53.0 Cr is tied up in the business at any time. FY26: customers took 53 days to pay and stock sat for 154 days, about 5.1 months of sales sitting as stock, for a full cycle of 115 days, longer than FY21's 83. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 154 days. Customers pay about 53 days after that. Suppliers are paid at 91 days. Together that makes the 115-day cycle. Spending on assets: ₹62.0 Cr over the last 3 years, against ₹8.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹46.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Jenburkt Pharmaceuticals' P/E ratio, and how does it compare with its own history? Jenburkt Pharmaceuticals Ltd's P/E is 14.3×, in the middle of its own history: higher than 59% of past readings. Its usual P/E (the middle reading) is 13.8×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Mar 2026 add up to ₹78.69. Why the multiple is where it is: over the past year earnings per share moved +8.4% while the price moved −13.7%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +18.2% a year; about +19.0% a year came from earnings growth and about −0.8 percentage points from the multiple (roughly no change); over 10 years the price moved +11.4% a year; about +14.0% a year came from earnings growth and about −2.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Jenburkt Pharmaceuticals share price assume? Worked out from its price on 13 June 2026, Jenburkt Pharmaceuticals Ltd's share price assumed profit growth of about 5.9% a year. Over the past 10 years its profit actually grew 12.3% a year. Today its P/E is 14.3×, higher than 59% of its own last 10 years. This is a one-day reading, taken on 13 June 2026. Every other number on this page, the multiple included, uses the latest price as of 24 June 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Jenburkt Pharmaceuticals business getting better or worse? Jenburkt Pharmaceuticals Ltd's business is growing steadily. Revenue and profit growth have stayed positive throughout, and ROCE is steady at 27.0% (four quarters to FY26). This is based on 9 quarters of 3 measures, with some gaps. Why it matters: steady growth with healthy returns is how a business compounds over time. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Jenburkt Pharmaceuticals earn on its capital? Jenburkt Pharmaceuticals Ltd earned a ROCE of 27% in FY26. That is up from a low of 24% in FY21. Its return on capital used (ROIC) is 9.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 20.7% net margin and 0.75× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 20.7% net margin × 0.75× asset turnover × 1.15× leverage (assets divided by equity) ≈ 17.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 21.5% − 12.0% = +9.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. ## Does Jenburkt Pharmaceuticals have too much debt? Jenburkt Pharmaceuticals Ltd had ₹2.0 Cr of borrowings against ₹197 Cr of equity in FY26, so its debt is 0.01× its equity. Over 5 years borrowings went from ₹5.0 Cr to ₹2.0 Cr. Over the last 3 of those years it spent ₹62.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Jenburkt Pharmaceuticals shareholding pattern? No group of Jenburkt Pharmaceuticals Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.1 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −0.6 points over 8 quarters, to 46.6%; Domestic institutions: +0.1 points over 8 quarters, to 0.1%; Foreign institutions: +0.0 points over 8 quarters, to 0.0%. ## How far is Jenburkt Pharmaceuticals from balance-sheet trouble? For Jenburkt Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Jenburkt Pharmaceuticals rank in its industry? 55.3 out of 100, rank 9 of 10 in Pharma - Others, with 47% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Jenburkt Pharmaceuticals Ltd scores 55.3 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 9. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 20.1 + 21.7 + 13.5 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Jenburkt Pharmaceuticals compared with? Jenburkt Pharmaceuticals ranks 9 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 55.3 out of 100. 1. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Most evidence points up · 60% evidence 70.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.8/35 · Revenue 100% · Profit 100% · Operating margin change 57 points · 95% evidence Capital efficiency 19.1/25 · ROCE 37% (year to Mar 2026) · Operating margin 50% · 76% evidence Valuation 9.5/20 · P/E 73.4× · PEG n/a · 15% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 79.5% · 1 year 101.1% · 25% evidence · 8 of 8 weeks ahead Exact sum: 29.8 + 19.1 + 9.5 + 12.5 = 70.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · leader · Most evidence points up · 83% evidence 66.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue 0.4% · Profit 50% · Operating margin change 7 points · 100% evidence Capital efficiency 18.1/25 · ROCE 24.7% (year to Mar 2026) · Operating margin 22.5% · 100% evidence Valuation 10.2/20 · P/E 21.7× · PEG n/a · 15% evidence Relative strength 18.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.3% · Strength vs NIFTY 500 (same reading) 27% · 1 year 38.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20 + 18.1 + 10.2 + 18 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Most evidence points up · 60% evidence 65.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 38.0/43.75 · Revenue 100% · Profit 100% · Operating margin change 109.9 points · 95% evidence Capital efficiency 16.5/31.25 · ROCE 16.8% (year to Mar 2026) · Operating margin 20.8% · 95% evidence Valuation 11.1/25 · P/E 169.2× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 38 + 16.5 + 11.1 = 65.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 4. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · turning · Evidence leans up · 81% evidence 60.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.0/35 · Revenue 100% · Profit 100% · Operating margin change 684 points · 74% evidence Capital efficiency 16.3/25 · ROCE 164% (year to Mar 2026) · Operating margin -153.3% · 100% evidence Valuation 15.0/20 · P/E 3.8× · PEG n/a · 50% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) -9.2% · Strength vs NIFTY 500 (same reading) 15.4% · 1 year 39.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18 + 16.3 + 15 + 11.2 = 60.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans down · 75% evidence 48.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% (year to Mar 2026) · Operating margin 1.7% · 100% evidence Valuation 14.7/20 · P/E 5.7× · PEG n/a · 50% evidence Relative strength 8.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -6.7% · 1 year -1.6% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.3 + 6.8 + 14.7 + 8 = 48.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · losing its lead · Evidence leans down · 66% evidence 48.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue 53.9% · Profit 83.3% · Operating margin change 3 points · 48% evidence Capital efficiency 13.9/25 · ROCE 11.5% (year to Mar 2026) · Operating margin 35.5% · 76% evidence Valuation 11.4/20 · P/E 30.6× · PEG n/a · 50% evidence Relative strength 4.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -19.4% · Strength vs NIFTY 500 (same reading) 3.1% · 1 year 17.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19 + 13.9 + 11.4 + 4 = 48.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · quiet · Evidence leans down · 67% evidence 36.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.3/35 · Revenue 6.4% · Profit 100% · Operating margin change 1 points · 71% evidence Capital efficiency 7.0/25 · ROCE 4.1% (year to Mar 2026) · Operating margin 11.6% · 76% evidence Valuation 10.8/20 · P/E 9.7× · PEG n/a · 15% evidence Relative strength 7.3/20 · Strength vs its industry (price vs its 52-week average, weekly) -14.3% · Strength vs NIFTY 500 (same reading) 9.2% · 1 year 0.5% · 100% evidence · 6 of 12 weeks ahead Exact sum: 11.3 + 7 + 10.8 + 7.3 = 36.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 74% evidence 28.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.1/35 · Revenue 19.5% · Profit 100% · Operating margin change 21 points · 74% evidence Capital efficiency 1.5/25 · ROCE -2.4% (year to Mar 2026) · Operating margin 8.4% · 100% evidence Valuation 9.2/20 · P/E 112× · PEG n/a · 15% evidence Relative strength 2.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -32.6% · Strength vs NIFTY 500 (same reading) -12.5% · 1 year -2.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 16.1 + 1.5 + 9.2 + 2 = 28.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. Jenburkt Pharmaceuticals Ltd this page Too little evidence to rank firmly · 47% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.1/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.7/31.25 · ROCE 27.2% (year to Mar 2026) · Operating margin 31.1% · 71% evidence Valuation 13.5/25 · P/E 14.3× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.1 + 21.7 + 13.5 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.9/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% (year to Mar 2025) · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 690.9× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 19.9 + 11.7 + 10.6 = 42.2 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Jenburkt Pharmaceuticals in size? Jenburkt Pharmaceuticals is the 10th largest of 10 Pharma - Others companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Syncom Formulations (India), Panacea Biotec, TTK Healthcare, JOJO, Remus Pharmaceuticals and Madhuveer Com 18 Network. It is the smallest. ### Pharma - Others companies close in size 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹2,058 crore 2. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹2,058 crore 3. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,569 crore 4. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,568 crore 5. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) ₹964 crore 6. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) ₹581 crore 7. Jenburkt Pharmaceuticals Ltd ₹498 crore [All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies) ### Companies close in size in other industries 1. [Davangere Sugar Company Ltd](https://www.sectoralpha.in/stocks/davangere-sugar-company-ltd) ₹499 crore · Sugar 2. [RMC Switchgears Ltd](https://www.sectoralpha.in/stocks/rmc-switchgears-ltd) ₹499 crore · Capital Goods - Switchgear 3. Jenburkt Pharmaceuticals Ltd ₹498 crore 4. [Brahmaputra Infrastructure Ltd](https://www.sectoralpha.in/stocks/brahmaputra-infrastructure-ltd) ₹498 crore · Construction - Civil/Turnkey 5. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) ₹497 crore · Trading ## What else do people ask about Jenburkt Pharmaceuticals? ### What were Jenburkt Pharmaceuticals's latest quarterly results? Jenburkt Pharmaceuticals Ltd reported revenue of ₹45.0 Cr and net profit of ₹11.0 Cr for the Mar 2026 quarter. Revenue rose 9.8% and profit rose 22.2% compared with a year earlier. Earnings per share were ₹24.58. The operating margin was 31.1%, 4.3 percentage points higher than a year earlier (as of 24 June 2026). ### What is Jenburkt Pharmaceuticals's market cap? Jenburkt Pharmaceuticals Ltd's market capitalisation is ₹498 Cr at a share price of ₹1,128.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 24 June 2026). ### How is Jenburkt Pharmaceuticals performing? Jenburkt Pharmaceuticals Ltd's share price has been rising for 3 weeks. In its latest quarter, revenue rose 9.8% and profit rose 22.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 13 weeks running (as of 24 June 2026). ### Will Jenburkt Pharmaceuticals's share price go up? This page does not forecast Jenburkt Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹1,128.10, and it has been rising for 3 weeks. Its P/E of 14.3× is higher than 59% of its own last 10 years (as of 24 June 2026). ### Who owns Jenburkt Pharmaceuticals? Promoters own 46.6% of Jenburkt Pharmaceuticals Ltd, foreign institutions 0.0%, domestic institutions 0.1% and the public 53.2% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 24 June 2026). ### Where is Jenburkt Pharmaceuticals in its business cycle? Jenburkt Pharmaceuticals Ltd's FY26 operating margin was 26.0%, against a 12-year range of 16.8% to 26.3%. The latest quarter was 31.1%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 24 June 2026). ### What could break the Jenburkt Pharmaceuticals story? Biggest thing to watch: the price has already been rising for 3 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 24 June 2026). ### Is Jenburkt Pharmaceuticals a stock worth studying right now? What the numbers show: Jenburkt Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +8.4% in a year while the price moved −13.7%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 24 June 2026). This is research, not advice. We’re not SEBI-registered.